Environmental Risk Assessment: ERA Reports

28.05.2020

LOGFILE Feature

Excerpt from our Guideline Evaluation of the environmental risks of medicinal products: ERA reports

8 min. reading time | by GMP Verlag Peither AG
Published in LOGFILE 22/2020

1. Introduction: environmental risk evaluation

Due to the increased levels of active pharmaceutical ingredients (APIs) in surface water and groundwater, soil, air, and biota, there is a need to assess their impact on organisms in the natural environment.

This guide aims to describe the evaluation of the potential environmental risks of medicinal products for human use. In addition, it includes considerations about possible precautions and safety measures to be taken, as well as a set of recommendations. Environmental Risk Evaluation (ERA) refers to risks related to the use, storage, and disposal of medicinal products and not to any risks resulting from the synthesis or manufacture of these product

2. Regulations

Based on the knowledge that APIs can pose an environmental risk and, in accordance with the provisions of Article 8(3) of Directive 2001/83/EC of the European Parliament on Medicinal Products for Human Use, the EMA (European Medicines Agency) published a guide that came into effect in 2006 (EMEA/CHMP/SWP/4447/00).

Furthermore, the German Federal Environmental Agency (UBA), one of the most prominent and active authorities in the field, evaluated a total of 120 environmental risk evaluations (ERA) in the years 2006-2014. Approximately 10% of the ERAs concluded that the pharmaceutical substance in question supposed an environmental risk.

Since the EMA guide came into effect, several subsequent changes have been made to the initial version. Furthermore, a Q&A document published in 2011 has been recently updated in order to clarify certain aspects of implementation of the guide.

Finally, a document published more recently by the EMA (EMA/CHMP/ SWP/65429/2016) presents a review of the environmental risk evaluation guide for medicinal products of human use (EMEA/CHMP/SWP/4447/00 corr 2) based on the latest available scientific knowledge. This review aims to provide a set of harmonised requirements for the ERA based on current scientific knowledge, as well as to optimise the tiered approach.

3. Evaluation Phases

The ERA employs a gradual approach consisting of two separate phases:

Get more information about ERA

Do you have any questions or suggestions? Please contact us at: redaktion@gmp-verlag.de

GMP-Verlag Published on 28 May 2020

You may also be interested in the following articles:

23.10.2026

News

EMA Clarifies Batch Numbering for Parallel-Traded Medicines

EMA updated its GMP/GDP Q&A collection by revising the answer to Question 4 concerning Chapter 5 of the EU GMP Guide. It explains which batch numbers should appear on the packaging of parallel-traded medicines.

19.10.2026

Question of the Week

Why is it Important to use Consistent Microbiological Air Monitoring Methods in Pharmaceutical Cleanrooms?

Here's the answer:

Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

19.10.2026

LOGFILE Feature

Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Robust PDE reports form the basis of risk-based cleaning validation. This article highlights common deficiencies identified during GMP inspections and explains how they can be avoided.

16.10.2026

News

EDQM: New Working Party on 3D-printed Medicinal Products

The European Pharmacopoeia Commission (EPC) approved the creation of a working party on 3D-printed medicinal products. Its aim is to support the development of appropriate quality standards in the European Pharmacopoeia (Ph. Eur.).

16.10.2026

News

EMA: 14 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.

WHO: Draft Revision of its Guidelines on Quality Risk Management

12.10.2026

News

WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO published a revised draft of its “WHO guidelines on quality risk management”. Working document QAS/26.994 is open for public comment until 15 November 2026.

Related Products

GMP Compliance Adviser | Named User Licence | 12M

With an named user licence, one user can access the knowledge portal; with a corporate licence, any number of users can access it.Approx. 5,000 pages of practical GMP knowledge with illustrations and forms: Practical guidance for rapid implementation in the workplaceDetailed descriptions of GMP-compliant systemsInternational laws and guidelines Always up-to-date thanks to regular updates Download Advantages and Prices60+ Sample Documents In addition, the GMP Compliance Adviser contains more than 60 sample documents (MS Office) and practical examples that you can use.Sample SOPsSample FormsSample ReportsSample DocumentationChecklistsProcess Diagrams (Flowcharts)Practical Examples of QRM Application (e.g., Risk Analyses)Sample Documents for Qualification and ValidationCase StudiesWritten by more than 80 authors with hands-on experience directly linked to the industryA team of over 80 experts interpret regulatory requirements and describe how they are implemented in practice.The authors are experienced in the pharmaceutical industry, consulting, and government agencies.

delivery immediately after receipt of payment

€1,368.00 net excl. VAT

Details

GMP:KnowHow Pharma Logistics (GDP) | Named User Licence | 12M

Your knowledge portal for GDP-compliant pharmaceutical logistics. It is important that you as a logistics service provider, but also as a client in the pharmaceutical industry, comply with regulatory requirements. The GMP:KnowHow knowledge portal guides you through the complex regulatory landscape of the pharmaceutical and logistical supply chain! The knowledge portal gives you an easy-to-understand overview of all the important topics. Interactive graphics help you navigate all areas covered by the EU GDP Guidelines (2013/C 343/01). You also have the relevant passages of the regulations directly at hand for each topic. This allows you to compare the requirements directly and saves valuable research time.One thing is certain: the knowledge portal answers your questions about the supply chain of medicinal products, active pharmaceutical ingredients and medical devices. You don't have to be an expert. Yet.You will find answers to your questions in the GMP:KnowHow Pharma Logistics (GDP). Where does GDP begin, where does GMP end? What does GDP-compliant mean? When do I also have to take GMP requirements into account? What permits do I need for certain activities? What requirements do I have to fulfil? What is the current legal basis? How am I covered? What authorizations do I have for my work, e.g. from my employer? Who is responsible — the client or the contractor? And many more What is the difference to the GMP Compliance Adviser? GMP:KnowHow Pharma Logistics (GDP) is a practical knowledge portal dedicated to Good Distribution Practice (GDP). It is a product that is independent of the GMP Compliance Adviser and concentrates on content that is essential for carriers of medicinal products, active pharmaceutical ingredients and medical devices as well as for logistics clients. The focus is on practical knowledge and how to apply it in your daily business. If necessary, the relevant regulations can be called up immediately alongside the practical knowledge, and you can see the relevant paragraphs at a glance. In addition, sample documents are available to help you make immediate progress. AuthorSimone Ferrante, currently Director Quality at Fisher Clinical Services, previously served as Head of Quality Control and Responsible Person (GDP) for the Grieshaber Group. She is also a long-standing author and GDP expert at GMP-Verlag.

delivery immediately after receipt of payment

€610.00 net excl. VAT

Details

E-Learning GMP:READY | Specialist Knowledge GMP for Engineers

Why are GMP rules important for technicians and engineers? Technicians and engineers play a key role in ensuring compliance with Good Manufacturing Practice (GMP) standards. They are involved in critical activities such as: planning and construction of ventilation systems, maintenance of water treatment plants, calibration of measuring sensors. Therefore, they are jointly responsible for the quality of medicines and must ensure that their work complies with GMP standards.Your advantages: Fast familiarization with GMP topics in approx. 2 hours, time- and location-independent online training, printable personal certificate, 12-month access for initial and follow-up training, automatic updates in case of legal changes,content compliant with Article 7(4) of Directive 2003/94/EC.The Author This e-learning course was developed with the collaboration of Dipl.-Ing. Andreas Nuhn (D & B Pharmadesign GmbH).

delivery time appr. 2-5 workdays after receipt of payment

€245.00 net excl. VAT

Details

GMP Fundamentals | A Step-by-Step Guide

This handbook is a practical and easy to read guideline, giving you a quick and comprehensive overview of the complex world of Good Manufacturing Practice (GMP) without the need of previously acquired knowledge. Some topics are: GMP: Purpose and basic pharmaceutical terms Laws, licenses and inspections Personnel: Responsibility and hygiene Standard Operating Procedures (SOP) and documentation Design of rooms and facilities Processing and packaging Quality control and market release Suppliers, storage and logistics (Good Distribution Practice = GDP) Alphabetical index and abbreviations Using practical examples and comparisons to every-day life will help to easy understand GMP regulations.GMP Fundamentals is a helpful guide which facilitates the entry into the GMP world and teaches the necessary basics.

delivery immediately after receipt of payment

€44.90 net excl. VAT

Details